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Abstract
Background The development of prostate cancer can be influenced by genetic and environmental factors. Numerous
germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase prostate
cancer susceptibility are unknown. Finasteride is currently not being used routinely as a chemoprevention agent but the long
term outcomes of the PCPT trial are awaited. The outcomes of the SELECT trial have not recommended the use of
chemoprevention in preventing prostate cancer. This study investigated whether germline risk SNPs could be used to predict
outcomes in the PCPT and SELECT trial.
Methods Genotyping was performed in European men entered into the PCPT trial (n= 2434) and SELECT (n= 4885).
Next generation genotyping was performed using Affymetrix® Eureka™ Genotyping protocols. Logistic regression models
were used to test the association of risk scores and the outcomes in the PCPT and SELECT trials.
Results Of the 100 SNPs, 98 designed successfully and genotyping was validated for samples genotyped on other platforms.
A number of SNPs predicted for aggressive disease in both trials. Men with a higher polygenic score are more likely to
develop prostate cancer in both trials, but the score did not predict for other outcomes in the trial.
Conclusion Men with a higher polygenic risk score are more likely to develop prostate cancer. There were no interactions of
these germline risk SNPs and the chemoprevention agents in the SELECT and PCPT trials.
Introduction
Prostate cancer accounts for a quarter of cancer diagnoses in
men in the UK and is the fourth most common cancer
worldwide with an estimated 1.1 million men diagnosed in
2012 [1]. Screening strategies have not led to their routine
clinical use in daily practice, due to an over-diagnosis of
indolent cancers [2].
Due to its biology, prostate cancer is ideally suited target
for chemoprevention because of its step-wise biological
development. Prostate cancer may have precursor lesions
such as atypical small acinar proliferation and high grade
prostatic intraepithelial neoplasia which may appear many
years before cancer is diagnosed. This high risk population
with these precursor lesions could be targeted for chemo-
prevention [3]. Prostate cancer also has a long latent period
from its development to its eventual clinical manifestation.
Chemoprevention could also be used to prevent these early
malignant lesions developing further and therefore many
men could be spared diagnostic procedures and potentially
toxic systemic treatments [4].
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It is thought that the risk of prostate cancer development
could be potentially modifiable by dietary and other lifestyle
factors. Large epidemiological studies have shown that
migrants who have moved from areas of low prostate cancer
incidence such as Korea and Japan to the USA have
developed prostate cancer rates similar to their native
inhabitants [5, 6]. Environmental factors are attributable to
this change of risk and some of these could be potentially
modifiable by dietary changes [6]. There are also causal
links between androgen exposure and the development of
prostate cancer, which is also potentially modifiable [7].
The need to answer the question of the role of chemopre-
vention in prostate cancer was the aim of two large ran-
domised controlled trials: The Prostate cancer Prevention
Trial (PCPT) and The Selenium and Vitamin E Cancer
Prevention Trial (SELECT). The biological rationale for the
agents used in the trial, trial schema and results can be
found in more detail elsewhere [8, 9]. In summary, 18,880
men were eligible and randomised on the PCPT to receive
placebo or finasteride. The results of the PCPT trial showed
that prostate cancer was detected in 803 of the 4368 men in
the finasteride group and 1147 of the 4692 men in the
placebo group who had data for analyses. There was a
24.8% reduction in prevalence over the 7-year period.
Tumours with a Gleason score 7–10 were more common in
the finasteride group (280 of 757 tumours (37.0%)), than in
the placebo group (237 of 1068 tumours (22.2%)) (P <
0.001 for the comparison between groups) [8]. The long-
term results of the PCPT trial showed that the 10 year
survival from prostate cancer was equivalent between the 2
groups [10].
In the SELECT trial, 35,533 men were randomised to
receive selenium or vitamin E, or both or neither. The
SELECT trial was closed early because the interim analysis
showed that neither selenium, vitamin E, nor the combi-
nation prevented prostate cancer. The long-term results of
the SELECT trial showed that men taking vitamin E had
increased incidence of prostate cancer compared with pla-
cebo, which was statistically significant [9]. Genetic varia-
tions influencing the effects of these chemoprevention
agents have been reported from the PCPT and SELECT
trials [11–14]. However these studies have only used a
candidate gene approach to look for association in com-
parison with our study which has followed up validated risk
single nucleotide polymorphisms (SNPs).
At the time of undertaking these analyses, 100 germline
risk SNPs had been identified in genome wide association
studies [15, 16]. The 100 SNPs account for ~33% of
familial risk of prostate cancer [16]. If polygenic risk scores
are calculated, the top 10% of men in the highest risk
stratum have an ~2.9-fold relative risk of prostate cancer
compared with the average of the population, whilst the top
1% of men have a 5.7-fold relative risk in comparison with
the population average [16]. If these polygenic SNP scores
could be incorporated into screening with the addition of
known risk factors (age, race, and family history (FHx)),
then men with the highest risk of prostate cancer develop-
ment could be targeted for more intensive screening or
intervention.
Traditional genotyping technologies are currently not
suited to provide fast accurate outputs that could be used in
prospective clinical trials [17]. Genotype calling from next
generation sequence techniques may be able to overcome
these issues and therefore be more suited for everyday
clinical use [18]. We have worked with Eureka Genomics
(Hercules, CA; previously affymetrix now ThermoFisher
Scientific) to design and validate a next generation geno-
typing assay in these analyses.
While the functional role of how these SNPs influence
cancer predisposition is under investigation, evidence sug-
gests that this may be through various pathways [19].
Therefore, the hypothesis underlying this study was that
common genetic variants involved in prostate cancer pre-
disposition may have a role in tumour formation but also
influence the effects of the chemoprevention agents. In
breast cancer, evidence has shown that chemoprevention
with tamoxifen reduces the risk of contralateral breast
cancer for those women who have variants in the BRCA2
gene [20]. The aim of this study was to investigate the
association of prostate cancer germline risk SNPs and their
influence on the chemoprevention agents in the PCPT and
SELECT trials.
Materials and methods
Patients
The details of the PCPT study can be found in more detail
elsewhere [8]. Informed consent as obtained from all
patients. In summary, healthy men aged 55 years or older,
with a normal digital rectal examination (DRE), American
Association Urology Score of less than 20 and no clinically
significant co-morbidity were entered into the trial. The
prostate specific antigen (PSA) on entry into the trial was
required to be 3.0 ng/ml or lower. Men were randomised to
receive Finasteride or placebo. The men underwent annual
DRE, and measurements of PSA. If the DRE was suspicious
for cancer or the adjusted PSA > 4.0 ng/ml, then these men
were recommended to undergo a prostate biopsy. If these
investigations were normal or biopsy was negative, men
were followed up for a total of 7 years and an end of study
biopsy was performed. The end of study biopsy identified
additional prostate cancers among men with neither a
sspicious DRE or elevated PSA and confirmed that the
controls did not have prostate cancer. A total of 18,880
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eligible men were randomised into the trial. Our institution
received DNA samples from 2434 cases and controls from
the PCPT study.
The details of the SELECT trial can found in more detail
elsewhere [21]. Healthy men entered the study and were
aged 55 years or over (Afro-American men were aged 50 or
older), had a normal DRE and a PSA ≤ 4 ng/ml. Participants
were randomised into one of four groups: Selenium alone,
vitamin E alone, selenium and vitamin E or placebo. Men
were followed every 6 months and suggested to have an
annual DRE and PSA. Men were recommended to undergo
PSA and DRE testing and prostate biopsy based on local
care guidelines. Upon a diagnosis of prostate cancer, men
were monitored annually.
A total of 35,553 men were randomised into the trial.
Our institution received DNA samples from 4885 men,
which were samples that were selected to be analysed as
part of a case-cohort study.
Laboratory methods, genotyping and quality
control
DNA was collected by white blood cells from participants
in the PCPT and SELECT trials and extracted at the
National Cancer Institute [22]. Thirty microlitres of DNA
was received at The Institute of Cancer Research; 5 µl was
sent for genotyping for the purpose of this analysis.
At the time of designing the genotyping assay the latest
100 SNP panel was used [23]. Supplementary Table 2 lists
the 100 known prostate cancer susceptibility SNPs at
that time.
The 100 SNP panel was developed by Affymetrix®, now
a part of ThermoFisher Scientific. The samples were gen-
otyped using the Affymetrix® Eureka™ Genotyping pro-
tocols. The Eureka genotyping assay is a ligation-dependent
PCR reaction, which uses interrogation site bar codes
contained within the ligation probes, as well as sample
index bar codes added during the amplification step. Next
generation sequencing libraries were created and short cycle
sequence data were generated from the prepared libraries.
Analysis software was used to tabulate the number of reads
that contain each combination of sample, locus and allele
bar code (as appropriate). The genotype was determined by
in-house software using Affymetrix® Eureka™ protocols.
In order to validate this new genotyping technique
two methods were used. Firstly, known genotypes of
overlapping samples from the iCOGs custom array and the
Affymetrix panel were contrasted [24]. Secondly the
observed minor allele frequencies from the Affymetrix
panel were compared with the genotypes of overlapping
samples on a custom high-throughput array by case and
control status [25]. The minor allele frequencies between
the two techniques were highly correlated (r2 > 0.99).
Standard quality control measures were applied to
remove variants with missing rates > 10% or displayed
genotype frequency deviating from those expected under
Hardy–Weinberg equilibrium (P < 0.05). Samples with less
than 90% genotyping rate were also removed (Table 1).
Measured outcome
On entry into the PCPT and SELECT trials, phenotypic
information was collected on all participants; further
detailed information on the phenotypic information col-
lected can be found in the individual trial protocols [26, 27].
Men who self-reported to be of European origin were
only included in this study as the vast majority of the
germline SNPs used in this analysis were discovered in
GWAS from populations of European descent. FHx was
defined as men who had one or more first degree relatives
affected with prostate cancer. Biopsies that were positive for
prostate cancer were reviewed by the local pathologist at the
participating centre, and for the PCPT trial and also
reviewed centrally [8, 21]. High-grade prostate cancer (non-
indolent prostate cancer) was defined as a Gleason score ≥ 7.
A summary of basic phenotype information for the DNA
received from PCPT and SELECT can be found here
(Table 2).
Statistical analysis
A polygenic risk score was calculated by summing the
genotype dosage for all variants for an individual. The log-
odds ratios used to weight the risk score were taken from
the OncoArray Meta-analysis [28]. Two types of risk score
were calculated:
Non-weighted, for patient i: risk scorei ¼
Pj
1 Gij
Weighted, for patient i: weighted risk scorei ¼
Pj
1 βjGij
j= variants 1–100
βj= is the per allele log-odds ratio for the risk of prostate
cancer associated with variant j
G= risk allele dosage
Table 1 Quality control for both studies
PCPT SELECT
Number of SNPs genotyped 98 98
Total number of DNA samples received 2435 4789
European 2089 3512
>10% Genotype missing for individual lost
Cases 0 47
Controls 0 67
SNP lost with less than 90% genotyping rate 5 9
Hardy–Weinberg equilibrium SNPs lost
(P < 0.001)
0 0
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Within each cohort of both trials age and body mass
index (BMI) were equally distributed. Logistic regression
was used to test the association of case/control and Gleason
score and the polygenic risk score. FHx was also used as a
covariate in the analyses. The polygenic risk score was
divided into quartiles for the logistic regression model and
interaction tested. For each individual SNP the χ2 test was
used to test the association with overall prostate cancer and
sub-strata defined by Gleason grade. Statistical significance
was determined at a level of P < 0.05. All analyses were
performed in the statistical package R 3.2.2 [29].
Power calculations
The power was calculated using the MAF and OR from the
Oncoarray paper which was the largest GWAS performed to
date [28]. A significance level of α= 0.05 was used and
calculated using a genetic power calculator [30]. The results
can be seen in Supplementary Table 1. The power ranged
for PCPT (5–96%) and SELECT (5–99%). The power was
greater in the SELECT trial as there were greater number of
participants the PCPT. Overall the study was underpowered
however there was a correlation between those with a high
power and the signal seen of the SNP in PCPT/SELECT. A
multiple comparison adjustment was not performed as
known variants were analysed in PCPT/SELECT. Power
was not calculated by randomisation arm as the power
would have been too low.
Results
The characteristics of the participants of the trial are sum-
marised in Table 2. Of the 100 SNPs, 98 SNPs were
designed successfully. Non-Europeans were removed from
the analysis and summary of the quality control is shown in
Table 3.
The single SNP association in both trials shows multiple
SNPs that are associated with developing prostate cancer at
a pre-defined significance level of P < 0.05 (Figs 1–3 and
Table 2 Patient characteristics
(FHx—family history)
PCPT SELECT
Finasteride Placebo Placebo Selenium Vitamin E Selenium &
vitamin E
Numbers
Total 833 1256 845 816 908 829
Cases 428 616 352 330 393 346
Control 405 640 493 486 515 483
Age
Mean age of entry
trial (SD)
64.4 (5.7) 63.6 (5.6) 63.9 (6.0) 63.8 (6.0) 64.0 (6.1) 63.7 (6.2)
Mean age of Ca
Dx (SD)
69.9 (5.6) 69.7 (5.7) 67.1(5.8) 63.8 (6.0) 67.6 (6.1) 67.2 (6.2)
BMI (kg/m2) 27.5 27.4 NA NA NA NA
FHx positive 195 263 180 149 188 178
Gleason ≤ 6 266 470 197 182 221 202
Gleason ≥ 7 157 138 123 115 143 114
Table 3 Showing the significant
single SNP association for the
development of prostate cancer
and nearby genes in PCPT trial
Trial arm Chromosome SNP P value Odds ratio Nearby genes
Placebo 3 rs7611694 0.04367 0.8473 SIDT1
Placebo 7 rs12155172 0.007637 1.292 SP8
Placebo 8 rs6983267 0.00198 0.78 N/A
Placebo 17 rs1859962 0.003917 1.26 N/A
Finasteride 2 rs7584330 0.03174 0.7799 MLPH
Finasteride 8 rs16901979 0.008784 2.28 N/A
Finasteride 17 rs4430796 9.64E-05 1.489 HNF1B
Finasteride 17 rs684232 0.03556 1.241 VPS53, FAM57A
Finasteride 17 rs1859962 0.01778 1.262 N/A
Finasteride 18 rs7241993 0.01109 0.7619 SALL3
Finasteride 22 rs5759167 0.01402 0.7852 BIL/TTLL1
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Tables 3 and 4). In the PCPT trial rs4430796 is associated
in the finasteride arm with development of prostate cancer;
the SNP resides near the gene HNF1B. There are also
multiple SNPs which are significant for the association with
high grade and low grade Gleason score (Table 5). In the
PCPT trial as the polygenic risk score increases the beta
predicting prostate cancer outcome increases and this is
statistically significant. With the addition of Finasteride the
beta reduces but it is not statistically significant (Table 6). In
the SELECT trial the polygenic risk score did not predict
cancer outcome except for those men who are in group 4 of
the weighted risk score. There was no interaction between
the interventions in the PCPT and SELECT trials and the
polygenic risk score.
In the PCPT trial, the use of drug intervention did predict
the outcome of developing high-grade prostate cancer, but
the chemopreventions in the SELECT trial were null
(Table 7). The weighted polygenic risk score was con-
sistently higher in cases than controls in all groups and this
was also statistically significant (P < 0.05) in both PCPT
and SELECT trials (Figs 4 and 5). Men in the study who
had a first degree relative with prostate cancer had a higher
polygenic SNP score in both studies, but this was not sta-
tistically significant (P > 0.05).
Fig. 1 Manhattan plot showing the single SNP association of the
placebo (above) and finasteride (below) arms in PCPT. Blue line
represents significance level P= 0.05
Fig. 2 Manhattan plot showing the single SNP association of the
placebo (above) and selenium (below) arms in SELECT. Blue line
represents significance level P= 0.05
Fig. 3 Manhattan plot showing the single SNP association of the
vitamin E (above) and selenium and vitamin E (below) arms in
SELECT. Blue line represents significance level P= 0.05
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention. . .
Discussion
This study confirmed that men in both the PCPT and
SELECT trials who developed prostate cancer had a higher
polygenic risk score than men who did not develop prostate
cancer. The study found no evidence that a high polygenic
risk score in combination with other risk factors such as
FHx could predict if the drug interventions could reduce
prostate cancer incidence or development of high grade
prostate cancer. Some individual SNPs were detected to
predict the likelihood of developing cancer in the individual
study arms but these analyses were limited by the power.
Rare variants such as those found in sequencing of BRCA1
and BRCA2 were not included in this analysis as they
require sequencing rather than genotyping in larger cohorts
using different statistical analyses. This study was limited to
prostate cancer risk associated with common variants of
European ancestry and is not useable in other ethnic groups.
The results of the PCPT trial showed a 24.8% reduction
in prostate cancer, but the chemoprevention in the SELECT
trial dud bit reduce prostate cancer incidence [8, 9]. Prostate
cancer SNPs are mostly found in intronic regions of genes,
and therefore functionally it is not clear how these SNPs
increase prostate cancer risk.
Genetic variations in the pathways in which the che-
moprevention agents act may influence the efficacy of the
agent. Finasteride acts by inhibiting the enzyme 5α reduc-
tase which is mediated by genes of the SRF5A family [31].
Polymorphisms in the SRFA genes have been reported
which affect the efficacy of Finasteride [32, 33]. Genetic
variations in the selenoprotein genes impact on plasma
selenium levels, and recent evidence suggests that this may
be associated with locally advanced or aggressive prostate
cancer [14]. Variations in vitamin E levels may also be
modified by genetic variations in vitamin E related genes
and an association between these and a lower incidence of
prostate cancer has been found [12]. If the above mechan-
isms that affect the outcome of these chemoprevention
agents were in common functional pathways with the
prostate cancer risk SNPs, men in the highest polygenic risk
score would be more likely to see some of the above ben-
efits from chemoprevention. Many of the pathways in
which these genetic variants affect drug efficacy remain
unknown, which therefore could be accounting for the null
results of this study.
In the single SNP association for the development of
prostate cancer a number of SNPs pass the significance
level. Functionally it is not clear how these associations are
linked but there are potentially some interesting regions.
One interesting SNP which was statistically significant in
the Finasteride arm of the PCPT trial was rs4430796 which
resides near the gene HNF1B [34]. This SNP is in strong
linkage disequilibrium with SNP rs757210. It has been
Table 4 Showing the significant single SNP association for the
development of prostate cancer and nearby genes in SELECT trial
Trial arm CHR SNP P OR Nearest gene
Placebo 1 rs636291 0.003377 0.6929 PEX14
Placebo 2 rs3771570 0.02715 1.404 FARP2
Placebo 6 rs4713266 0.01558 0.7583 TNS3
Placebo 8 rs1512268 0.05006 1.252 NKX3.1
Placebo 10 rs2252004 0.04196 0.683 N/A
Placebo 11 rs11214775 0.02261 0.7473 HTR3B
Placebo 12 rs1270884 0.04148 0.7919 TBX5
Placebo 17 rs1859962 0.002107 1.422 N/A
Placebo 23 rs5919432 0.006584 1.712 AR
Selenium 2 rs12621278 0.0256 0.563 ITGA6
Selenium 5 rs2242652 0.05695 0.7398 TERT
Selenium 8 rs2928679 0.04767 1.268 SLC25A37
Selenium 10 rs10993994 0.01418 1.345 MSMB
Selenium 10 rs2252004 0.05719 1.465 N/A
Selenium 11 rs1938781 0.0172 0.699 FAM111A
Selenium 12 rs80130819 0.03519 0.6222 N/A
Selenium 17 rs1859962 0.04747 1.267 N/A
Selenium 20 rs6062509 0.01023 0.7144 ZGPAT
Vit E 3 rs2660753 0.00565 1.659 N/A
Vit E 4 rs7679673 0.01517 0.7443 TET2
Vit E 6 rs2273669 0.04909 1.383 ARMC2,
SESN1
Vit E 8 rs1512268 0.04919 1.261 NKX3.1
Vit E 10 rs10993994 0.03971 1.28 MSMB
Vit E 11 rs11214775 0.001709 0.661 HTR3B
Vit E 11 rs1938781 0.02891 0.7233 FAM111A
Vit E 11 rs7127900 0.03343 1.365 N/A
Vit E 11 rs7931342 0.03694 0.7825 N/A
Vit E 17 rs138213197 0.05212 3.532 N/A
Sel+Vit E 2 rs12621278 0.01127 0.5422 ITGA6
Sel+Vit E 2 rs10187424 0.03605 1.264 GGCX/
VAMP8
Sel+Vit E 2 rs11902236 0.0422 1.275 TAF1B:
GRHL1
Sel+Vit E 8 rs1447295 0.0118 1.556 N/A
Sel+Vit E 8 rs620861 0.01228 0.7508 N/A
Sel+Vit E 8 rs12543663 0.04453 1.273 N/A
Sel+Vit E 9 rs1571801 0.02191 0.7455 DAB21P
(aggressive
SNP)
Sel+Vit E 11 rs11568818 0.01959 0.7711 MMP7
Sel+Vit E 14 rs8014671 0.05637 1.237 N/A
Sel+Vit E 17 rs1859962 0.05754 1.234 N/A
Sel+Vit E 20 rs2427345 0.05815 0.8051 GATAS,
CABLES2
Sel+Vit E 23 rs5945619 0.000263 1.808 NUDT11
Sel+Vit E 23 rs2405942 0.0367 0.6727 SHROOM2
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reported that inheriting the risk allele for one of these SNPs
increases the likelihood of developing prostate cancer (OR
= 1.22, 95% CI 1.15–1.30; P= 1.4 × 10–11), but reduces the
risk of developing type 2 diabetes (OR= 0.91, 95% CI
0.88–0.93; P= 8 × 10–10) [35]. The association between the
phenotypes of type 2 diabetes and prostate cancer was
further investigated in the PCPT trial. This showed that type
2 diabetes was associated with a 47% reduction of low
grade prostate cancer and 28% reduction of high grade
prostate cancer [36]. When the authors looked at the asso-
ciation of obesity and prostate cancer they found that
increased obesity reduced low grade prostate cancer but
Table 5 Showing the significant
single SNP association of high
and low grade Gleason score
and nearby genes in PCPT and
SELECT trial
Trial CHR SNP P OR Nearest gene
SELECT 1 rs1218582 0.2969 0.8991 N/A
SELECT 1 rs636291 0.000788 0.6965 PEX14
PCPT 2 rs721048 0.02 1.487 EHBP1
SELECT 2 rs12621278 0.009552 0.563 ITGA6
SELECT 2 rs3771570 0.02863 1.35 FARP2
PCPT 3 rs2055109 0.01 0.6528 N/A
SELECT 3 rs2660753 0.00946 1.505 N/A
SELECT 3 rs10934853 0.01466 1.316 N/A
PCPT 5 rs2853676 0.04 1.368 N/A
PCPT 5 rs13190087 0.01 2.398 N/A
SELECT 5 rs2242652 0.02988 0.7401 TERT
PCPT 6 rs2273669 0.02 1.535 ARMC2, SESN1
SELECT 6 rs2273669 0.03273 1.324 ARMC2, SESN1
SELECT 6 rs2273669 0.03308 1.355 ARMC2, SESN1
SELECT 7 rs12155172 0.0316 1.281 N/A
PCPT 8 rs620861 0.02 0.6856 N/A
PCPT 8 rs11135910 0.05 0.6722 EBF2
SELECT 8 rs12543663 0.04911 1.24 N/A
SELECT 8 rs1512268 0.02339 1.254 NKX3.1
SELECT 8 rs1447295 0.02999 1.387 8q24
SELECT 8 rs16901979 0.003904 2.109 N/A
PCPT 10 rs3850699 0.04 1.343 TRIM8
SELECT 10 rs10993994 0.008375 1.315 MSMB
SELECT 10 rs2252004 0.003301 0.6115 N/A
PCPT 11 rs7127900 0.04 0.6679 N/A
PCPT 11 rs1938781 0.04 1.386 FAM111A
SELECT 11 rs1938781 0.01914 0.7441 FAM111A
SELECT 11 rs11214775 0.000796 0.6819 HTR3B
SELECT 11 rs11568818 0.01808 0.7962 MMP7
PCPT 12 rs10875943 0.02 1.439 TUBA1C/PRPH
SELECT 12 rs1270884 0.04893 0.8222 TBX5
SELECT 12 rs80130819 0.01114 0.6233 N/A
SELECT 14 rs8014671 0.03711 1.224 N/A
SELECT 17 rs1859962 0.004161 1.328 N/A
SELECT 17 rs138213197 0.005718 NA N/A
SELECT 17 rs1859962 0.009122 1.3 N/A
SELECT 20 rs6062509 0.001863 0.71 ZGPAT
SELECT 22 rs5759167 0.02545 0.8011 N/A
SELECT 22 rs9623117 0.03146 0.7666 N/A
SELECT 23 rs5919432 0.003371 1.662 AR
SELECT 23 rs5945619 3.75E-05 1.784 NUDT11
SELECT 23 rs2405942 0.01501 0.6641 SHROOM2
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increased high grade prostate cancer [36].The authors also
showed that there was no correlation between obesity and
type 2 diabetes, suggesting an independent pathway in
which diabetes protects against prostate cancer. Our ana-
lysis supports these data which shows that diabetes inci-
dence is lower in men who develop prostate cancer in the
placebo arm and inherit one of the SNPs near HNF1B.
However this association is not seen in men who have
Finasteride who have higher rates of type 2 diabetes and
could possibly suggest a metabolic interaction between the
drug and the SNP.
On analyses of the SNP association with high grade and
low grade Gleason score a number of SNPs show an
association with Gleason grade in the individual trial arms.
An example in the Finasteride arm of the PCPT, SNP
rs7127900 showed a statistically significant reduction in the
odds ratio of developing high grade prostate cancer (P=
Table 6 Polygenic risk score analyses results. P value corresponding
to beta estimate. Weighted polygenic risk score weighted by log-
odds ratio
Beta P
Unweighted polygenic risk score PCPT
SNP score category 2 0.45 0.001
SNP score category 3 0.67 3E−06
SNP score category 4 1.01 8E−15
Drug 0.09 0.33
Weighted polygenic risk score PCPT
SNP score category 2 0.4 0.01
SNP score category 3 0.57 0.00002
SNP score category 4 0.79 1E−08
Drug 0.1 0.29
Unweighted polygenic risk score SELECT
SNP score category 2 0.13 0.6
SNP score category 3 0.08 0.68
SNP score category 4 0.2 0.31
Selenium 0.21 0.28
Vitamin E 0.13 0.5
Selenium & vitamin E 0.08 0.7
Weighted polygenic risk score SELECT
SNP score category 2 0.23 0.04
SNP score category 3 0.23 0.04
SNP score category 4 0.52 5E−08
Selenium −0.04 0.66
Vitamin E 0.07 0.48
Selenium & vitamin E 0 0.65
Table 7 Showing weighted polygenic risk score, trial drug and family
history predicting Gleason score
Weighted SNP score to predict Gleason Cat
(HG/LG) using drug and family history
Beta P
PCPT
SNP score category 2 0.44 0.11
SNP score category 3 0.41 0.1
SNP score category 4 0.14 0.57
Drug 0.69 0.0000007
Family history −0.02 0.9
SELECT
SNP score category 2 −0.56 0.003
SNP score category 3 −0.17 0.33
SNP score category 4 −0.28 0.08
Selenium 0 1
Vitamin E 0.03 0.84
Selenium & vitamin E −0.09 0.6
Family history −0.15 0.23
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Fig. 4 Boxplot showing the weighted polygenic risk score which is
higher in cases than controls and is statistically significant (P < 0.05) in
the PCPT trial
Sel Cases 
Sel Controls 
Sel Vit E 
Controls
Sel Vit E 
Cases
Placebo 
Cases 
Placebo 
Controls
Vit E 
Cases 
Vit E 
Controls
0.014
0.016
0.018
0.020
0.022
0.024
0.026
SN
P 
Sc
or
e 
Fig. 5 Boxplot showing the weighted polygenic risk score which is
higher in cases than controls and is statistically significant (P < 0.05) in
the SELECT trial
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0.04, OR= 0.67). Interestingly SNP rs7127900 has been
shown to have a biological interaction with insulin-like-
growth-factor-2 [37]. Analyses from the PCPT trial have
shown that serum levels of IGF were not correlated with
prostate cancer development; however, men who have high
levels of IGF are more likely to be on anti-diabetic drugs
such as metformin which have shown to have anti-cancer
properties [38]. In the SELECT trial SNP rs12621278 in the
vitamin E arm was also associated with a reduced odds ratio
of developing high grade prostate cancer. The SNP
rs12621278 resides near the integrin gene ITGA6 which has
been shown to be associated with prostate cancer progres-
sion and development [39]. Vitamin E could possibly be
interacting with this pathway [40].
So far 33% of common genetic variants that predict the
familial risk of prostate cancer have been discovered [16].
Men in the top 1% risk distribution have a 5.7-fold relative
risk of developing prostate cancer compared with the
average population being profiled [24]. The National
Institutes of Health GAME-ON initiative has discovered a
further 63 new prostate cancer susceptibility SNPs. Further
work needs to be performed to understand if these new
SNPs will help understand the biological rationale for
chemoprevention [28].
In summary this work has shown that a high polygenic
risk score can predict the development of prostate cancer
but there is no interaction with chemoprevention agents
such as finasteride and selenium/vitamin E. This is an
important null finding as population risk stratification will
be undertaken in coming years for disease detection and
prevention strategies. There is therefore no evidence from
these results that certain risk groups are individually more
likely to benefit from these two types of chemoprevention
and other types of agent will need to be tested to try to
reduce risk of high grade cancers in men with higher
polygenic risk scores.
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